Gallium scans, Gastric Emptying, MUGA scans, and Spect Brain scans are just a few of the scans that were formed, thanks to the nuclear medicine of today. In 1896, a man by the name of Henri Becquerel discovered that uranium penetrating rays were similar to X-rays. This leads to other numerous discovers like the finding of elements polonium and radium, to the cyclotron invented by Ernest Lawrence that included the ability to produce radioisotopes of different elements. This leads to 1946, where the nuclear reactor in Oak Ridge, U.S. , was opened for radionuclide production which leads to today. People should advance on the use of nuclear medicine because we are able to detect diseases, treat terrible diseases like cancer, and further research
…show more content…
For example, Radioimmunotherapy is where the radioactive material is tagged with an antibody that targets certain cancer cells. A great example of Radioimmunotherapy comes while treating Non-Hodgkin Lymphoma, an article that was in the Journal of Clinical Oncology Volume 26 written by Oliver W. Press (he is from Fred Hutchinson Cancer Research Center and University of Washington) talks about studies done on the use of Radioimmunotherapy and how 414 patients in either partial remission or complete remission after completing a variety of chemotherapy induction regimens were affected. People randomly were assigned to two groups, one where they were consolidated with RIT(Radioimmunotherapy) or not. It was found that after RIT consolidation, 77% of patients who were in partial remission after chemotherapy had gone to complete remission after RIT. Radioimmunotherapy ability to target specific cells and its low toxicity allows it to be a great choice while fighting …show more content…
A great example of these improvements is the possibility of diagnosing Alzheimer’s before symptoms occur. An article named “Alzheimer's and Dementia Testing for Earlier Diagnosis” written by the Alzheimer’s Association talks about the huge benefits that come out of targeting Alzheimer's in earlier stages before causing irreversible brain damage. The Alzheimer's Association wanted to find potential biomarkers that will allow to detect early stages of the disease, and so far Brain Imaging/Neuroimaging have been the top contender. There has been the development of tracers such as Florbetapir F-18 which during a PET(Positron Emission Tomography) brain scan reveals amyloid plaques in the brain of tested patients. Others that have been made are Flutemetamol F18 (approved in 2013) which binds and reveals the amyloid plaque. Florbetaben F18 (approved in 2014), also attaches and reveals to amyloid plaques in the brain while during a PET scan. The problem with this is that not all people with amyloid plaques experience any symptoms of Alzheimer's so amyloid plaques cannot be used to diagnose a patient . But with nuclear medicine, much information was able to be retrieved about the disorder, such as the PET scans revealed that people with Alzheimer's typically have reduced brain cell
For example, Radioimmunotherapy is where the radioactive material is tagged with an antibody that targets certain cancer cells. A great example of Radioimmunotherapy comes while treating Non-Hodgkin Lymphoma, an article that was in the Journal of Clinical Oncology Volume 26 written by Oliver W. Press (he is from Fred Hutchinson Cancer Research Center and University of Washington) talks about studies done on the use of Radioimmunotherapy and how 414 patients in either partial remission or complete remission after completing a variety of chemotherapy induction regimens were affected. People randomly were assigned to two groups, one where they were consolidated with RIT(Radioimmunotherapy) or not. It was found that after RIT consolidation, 77% of patients who were in partial remission after chemotherapy had gone to complete remission after RIT. Radioimmunotherapy ability to target specific cells and its low toxicity allows it to be a great choice while fighting …show more content…
A great example of these improvements is the possibility of diagnosing Alzheimer’s before symptoms occur. An article named “Alzheimer's and Dementia Testing for Earlier Diagnosis” written by the Alzheimer’s Association talks about the huge benefits that come out of targeting Alzheimer's in earlier stages before causing irreversible brain damage. The Alzheimer's Association wanted to find potential biomarkers that will allow to detect early stages of the disease, and so far Brain Imaging/Neuroimaging have been the top contender. There has been the development of tracers such as Florbetapir F-18 which during a PET(Positron Emission Tomography) brain scan reveals amyloid plaques in the brain of tested patients. Others that have been made are Flutemetamol F18 (approved in 2013) which binds and reveals the amyloid plaque. Florbetaben F18 (approved in 2014), also attaches and reveals to amyloid plaques in the brain while during a PET scan. The problem with this is that not all people with amyloid plaques experience any symptoms of Alzheimer's so amyloid plaques cannot be used to diagnose a patient . But with nuclear medicine, much information was able to be retrieved about the disorder, such as the PET scans revealed that people with Alzheimer's typically have reduced brain cell